MD3775165T2 - Procese de producție a limfocitelor infiltrante în tumori și utilizările acestora în imunoterapie - Google Patents

Procese de producție a limfocitelor infiltrante în tumori și utilizările acestora în imunoterapie

Info

Publication number
MD3775165T2
MD3775165T2 MDE20210111T MDE20210111T MD3775165T2 MD 3775165 T2 MD3775165 T2 MD 3775165T2 MD E20210111 T MDE20210111 T MD E20210111T MD E20210111 T MDE20210111 T MD E20210111T MD 3775165 T2 MD3775165 T2 MD 3775165T2
Authority
MD
Moldova
Prior art keywords
tils
expanding
infiltrating lymphocytes
immunotherapy
processes
Prior art date
Application number
MDE20210111T
Other languages
English (en)
Inventor
Seth Wardell
James Bender
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/940,901 external-priority patent/US10918666B2/en
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of MD3775165T2 publication Critical patent/MD3775165T2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0236—Mechanical aspects
    • A01N1/0242—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Prezenta invenţie prevede metode îmbunătăţite şi/sau simplificate de expansiune TIL-urilor şi producerea de populaţii terapeutice de TIL aşa cum se defineşte în revendicările anexate, inclusiv metode noi de expansiune a limfocitelor infiltrante în tumori (TIL) într-o populaţie terapeutică de TIL, pentru extinderea populaţiilor TIL într-un sistem închis, care conduc la o eficacitate îmbunătăţită, la îmbunătăţirea fenotipului şi la creşterea sănătăţii metabolice a TIL-urilor într-un timp mai scurt, perioadă de timp, permiţând în acelaşi timp reducerea contaminării microbiene, precum şi reducerea costurilor. Astfel de TIL-uri îşi găsesc utilizare în tratament terapeutic.
MDE20210111T 2018-03-29 2018-06-29 Procese de producție a limfocitelor infiltrante în tumori și utilizările acestora în imunoterapie MD3775165T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/940,901 US10918666B2 (en) 2017-03-29 2018-03-29 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
PCT/US2018/040474 WO2019190579A1 (en) 2018-03-29 2018-06-29 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Publications (1)

Publication Number Publication Date
MD3775165T2 true MD3775165T2 (ro) 2024-09-30

Family

ID=63013105

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20210111T MD3775165T2 (ro) 2018-03-29 2018-06-29 Procese de producție a limfocitelor infiltrante în tumori și utilizările acestora în imunoterapie

Country Status (21)

Country Link
EP (2) EP3775165B1 (ro)
KR (1) KR20200138329A (ro)
CN (1) CN112513254A (ro)
AU (1) AU2018415814A1 (ro)
BR (1) BR112020019496A2 (ro)
CA (1) CA3094957A1 (ro)
DK (1) DK3775165T3 (ro)
EA (1) EA202092319A1 (ro)
ES (1) ES2982509T3 (ro)
FI (1) FI3775165T3 (ro)
HR (1) HRP20240850T1 (ro)
IL (1) IL277592A (ro)
LT (1) LT3775165T (ro)
MD (1) MD3775165T2 (ro)
MX (1) MX2020010264A (ro)
PL (1) PL3775165T3 (ro)
PT (1) PT3775165T (ro)
RS (1) RS65674B1 (ro)
SG (1) SG11202009170UA (ro)
SI (1) SI3775165T1 (ro)
WO (1) WO2019190579A1 (ro)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP4077641A1 (en) 2019-12-20 2022-10-26 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
EP4107173A1 (en) * 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2022111571A1 (zh) 2020-11-25 2022-06-02 上海君赛生物科技有限公司 肿瘤浸润淋巴细胞培养基及其应用
CA3205464A1 (en) * 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
JP2024500748A (ja) * 2020-12-18 2024-01-10 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球の処理
CN114686430A (zh) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 一种制备til的方法
KR102666931B1 (ko) * 2021-03-30 2024-05-20 주식회사 네오젠티씨 면역세포 조성물을 생산하는 방법
CA3223030A1 (en) * 2021-06-17 2022-12-22 CBio A/S Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use
WO2023218399A1 (en) * 2022-05-11 2023-11-16 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Method of preparing and expanding a population of immune cells for cancer therapy, potency assay for tumor recognition, biological vaccine preparation and epitope target for antibodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
DK0766745T3 (da) 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
NZ334691A (en) 1996-10-11 2000-12-22 Bristol Myers Squibb Co Compositions of anti-4-1BB antibody effective for immunomodulation and treatment of T-cell autoimmune disease
AU2002220002B2 (en) 2000-10-31 2006-12-14 Evonik Corporation Methods and compositions for enhanced delivery of bioactive molecules
US6887673B2 (en) 2002-07-30 2005-05-03 Bristol-Myers Squibb Company Humanized antibodies against human 4-1BB
EP1687400A4 (en) 2003-10-08 2009-01-07 Wolf Wilson Mfg Corp METHODS AND DEVICES FOR CELL CULTURE USING GAS PERMEABLE MATERIALS
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA3201163A1 (en) 2005-07-01 2007-01-11 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP3072903B1 (en) 2007-07-10 2017-10-25 Apogenix AG Tnf superfamily collectin fusion proteins
WO2010003766A2 (en) 2008-06-17 2010-01-14 Apogenix Gmbh Multimeric tnf receptors
US8450460B2 (en) 2008-07-21 2013-05-28 Apogenix Gmbh Single-chain TNFSF fusion polypeptides
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
JP2013512694A (ja) 2009-12-08 2013-04-18 ウィルソン ウォルフ マニュファクチャリング コーポレイション 養子細胞療法のための細胞を培養する方法
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
BR112013005699B1 (pt) 2010-09-09 2021-08-17 Pfizer Inc Anticorpo isolado ou porção de ligação ao antígeno do mesmo que se liga ao 4-1bb humano, combinação, usos dos mesmos, bem como composição farmacêutica, molécula de ácido nucleico isolada e vetor
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
KR102591732B1 (ko) 2010-11-12 2023-10-19 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20140234320A1 (en) 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
CN102816734A (zh) * 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法
IL307674A (en) 2012-05-18 2023-12-01 Wilson Wolf Mfg Corporation Improved cell culture methods for stress cell therapy
CN110241086A (zh) 2012-06-11 2019-09-17 威尔逊沃夫制造公司 用于过继细胞疗法的改进的细胞培养方法
JP6416131B2 (ja) 2013-03-01 2018-10-31 アメリカ合衆国 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
CA2916244A1 (en) 2013-06-24 2014-12-31 Wilson Wolf Manufacturing Corporation Closed system device and methods for gas permeable cell culture process
TW201613635A (en) 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
WO2015157636A1 (en) * 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
WO2015189357A1 (en) 2014-06-11 2015-12-17 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
FR3040396A1 (fr) * 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
JOP20190224A1 (ar) * 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي

Also Published As

Publication number Publication date
IL277592A (en) 2020-11-30
SI3775165T1 (sl) 2024-09-30
EP4386080A2 (en) 2024-06-19
CA3094957A1 (en) 2019-10-03
ES2982509T3 (es) 2024-10-16
DK3775165T3 (da) 2024-07-08
RS65674B1 (sr) 2024-07-31
CN112513254A (zh) 2021-03-16
EP3775165A1 (en) 2021-02-17
HRP20240850T1 (hr) 2024-09-27
BR112020019496A2 (pt) 2021-01-12
PT3775165T (pt) 2024-07-17
EP3775165B1 (en) 2024-03-27
AU2018415814A1 (en) 2020-10-22
PL3775165T3 (pl) 2024-08-19
MX2020010264A (es) 2020-11-06
WO2019190579A1 (en) 2019-10-03
SG11202009170UA (en) 2020-10-29
EA202092319A1 (ru) 2021-03-04
KR20200138329A (ko) 2020-12-09
FI3775165T3 (fi) 2024-07-01
LT3775165T (lt) 2024-07-10

Similar Documents

Publication Publication Date Title
MD3775165T2 (ro) Procese de producție a limfocitelor infiltrante în tumori și utilizările acestora în imunoterapie
MD3601533T2 (ro) Procese de producţie a limfocitelor infiltrante în tumori și utilizările acestora în imunoterapie
PH12021551033A1 (en) Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
MX2020011134A (es) Proceso cerrado para expansion y edicion de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
MX2019012233A (es) Anticuerpos anti-sirpa.
CA3155727A1 (en) Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
PH12018502056A1 (en) Methods of treatment of cholestatic diseases
AU2017382297A8 (en) Phosphodiesterase inhibitors and methods of microbial treatment
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
WO2021226061A8 (en) Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
TW201613636A (en) Methods of treating Alzheimer's Disease
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
EA201891609A1 (ru) Производные 3-((гетеро-)арил)алкил-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
NO20055741L (no) Nye kjemiske forbindelser
EA201891611A1 (ru) Роизводные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
TW200504402A (en) Antimicrobial lenses, processes to prepare them and methods of their use
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2021006503A (es) Métodos para la expansión in vivo selectiva de poblaciones de células t gamma delta y composiciones de estas.
MX2016015574A (es) Composiciones esterilizadas de las proteinas ivig y kh para modular los linfocitos y tratar el virus de la hepatitis b.
ATE455789T1 (de) Substituierte nonadepsipeptide
EP4074818A3 (en) Tissue organoids
TWD183801S (zh) 耳圈